Skip to main content
. 2021 Jul 7;22(14):7310. doi: 10.3390/ijms22147310

Figure 4.

Figure 4

Strategies for pharmacological inactivation of ANGPTL3. Various strategies have been developed to pharmacologically inactivate ANGPTL3, which include blocking monoclonal antibodies (such as Evinacumab), antisense oligonucleotides (such as Vupanorsen), and a CRISPR genome editing system (such as base editor 3, BE3) for treatment of dyslipidemia. The development of oral, small-molecule inhibitors may serve as a novel pharmacological approach for ANGPTL3 inactivation (created with BioRender.com, accessed on 2 July 2021).